Opportunity Assessment
We have the expertise to conduct a thorough investigation of various disease areas across global markets by reviewing clinical differentiators, economic/ HTA value drivers, and future expectations leading to comprehensive understanding of potential opportunities
Understand
Indication Needs
Policy / Guidelines
Treatment guidelines, segment evidence requirements
Evaluate Competitor
ability to address needs
Reference Products
Price leader, market share leader, clinical SoC
Understand PRMA potential
based on competitive values
Pricing
Price evaluation by market, price structure assessment, drivers for price changing
Assess impact of future
landscape on value definition
Pipeline Products
Most promising competitors, indications, expected access restrictions, and postitioning
For each market and therapeutic area, we will
Clinical &
Economic Burden
Overall disease burden across countries and regions
Competitive
Performance
Competitive performance within the therapeutic basket
Reimbursement
HTA recommended reimbursement criteria across therapies
Future Dynamics
Changing pricing dynamics, introductions of generics policy changes
Analog Assessment
MKTXS adapts a Harvard Business methodology to develop custom recommendations for key unanswered market access concerns faced by our clients. The process involves scanning the healthcare industry to identify a mosaic products that have faced some or multiple similar challenges, conducting an in-depth similar parallel investigation into business issues and creating insights to proactively mitigate or reactively defend the market pricing access and reimbursement potential of our client’s assets.
